AI Security

Showing 11348 articles
Business

Shionogi Shares Surge as Cost Discipline Drives Profits Higher Than Sales

Japanese pharmaceutical firm Shionogi & Co. reported robust nine-month results, with net income growth significantly outpacing revenue increases. The performance highlights the company's effective cost management and strategic portfolio shifts, though analysts caution that future growth hinges on key pipeline products and regulatory approvals.

Business

Novo Nordisk's CagriSema Shows Superior Efficacy in Phase 3 Diabetes Trial, Bolstering Pipeline and Valuation Outlook

Novo Nordisk's combination therapy CagriSema has outperformed semaglutide in a pivotal Phase 3 trial for type 2 diabetes, significantly reducing blood sugar and weight. The strong results set the stage for regulatory discussions and reinforce the company's dominance in the metabolic treatment arena, amid heightened investor focus on its long-term growth potential.